The OXYMED website was purposed as an educational resource to medical and allied health care professionals (TGA Code (No.2) 2018 30 July 2019). The majority of patients attending OXYMED for Hyperbaric Oxygen Therapy are medical referrals and individual clients exercising their rights and entitlements under self-treatment and self-management. However, in accordance with the TGA (16 July 2020), all medical content and reference has been removed (in excess of 3,500 pages).

  • Patients are referred from medical and other health care professionals or self-referred, for “supporting care to assist (ameliorate) their condition and well-being care”. 

  • OXYMED does not provide the “primary” treatment of the patient’s condition or offer “cure, prevention, diagnosis (including screening), monitoring or susceptibility of, or predisposition” (TGA Section 30).

Hyperbaric Oxygen Therapy (HBOT) includes the inhalation of 100% oxygen at pressures exceeding one atmosphere absolute (1 ATA) in order to enhance the amount of oxygen dissolved in the body’s tissues. During HBOT treatment, the arterial O2 tension typically exceeds 2000 mmHg, and levels of 200–400 mmHg occur in tissues.

Historically, HBOT has been applied worldwide mostly for chronic non-healing wounds. HBOT has been recognized as a conventional medical treatment for decades and has been used to treat chronic indications such as ischemic non-healing wounds and delayed radiation injury.


Accordingly, the safety profile of HBOT, when used appropriately, is considered to be high with generally infrequent, reversible potential side effects. In recent years, there is growing evidence related to the regenerative effects of HBOT, in particular, that the combined action of both hyperoxia and hyperbaric pressure, leads to significant improvement in tissue oxygenation while targeting both Oxygen and pressure sensitive genes, resulting in improved mitochondrial metabolism with anti-apoptotic and anti-inflammatory effects.

What is Hyperbaric Therapy Tier 2?

‘Intermittent, short term, high dose Oxygen inhalation whilst under pressure’​

  • HBOT provides the body with greater opportunity for healing by increasing oxygen concentration in the body by up to 1,200%.

  • HBOT may inhibit anaerobic bacteria, viruses and other microbes that cannot survive in oxygenated environments.

  • Hyperbaric Medicine is a method of delivering elevated doses of Oxygen to the body. It is done by breathing 100% O2 through a mask or hood while inside a pressurized air chamber.

  • The pressure at Tier 2 (1.5-2.4 ATA) inside the chamber causes the (100%) Oxygen you breathe to be dissolved at greater levels in your blood is the same way that pressure causes carbon dioxide to be dissolved in soft drinks. The net effect is to increase Oxygen concentrations (tension) within the blood, which is then driven into the ‘targeted tissue’.

  • Hyperbaric pressure saturates Oxygen into energy deprived (hypoxic) structures inhibiting infections, reducing the effects of cytotoxic inflammatory cytokines and accumulating endotoxins. Hyperbaric Oxygenation up-regulates and promotes the body's own target specific stem cells and growth factors. 

Cytokine Gene Expression Testing is at the forefront of medical advances and immunotherapy interventions however not entirely new. 

The first member of the cytokine storm family to be recognized by physicians was sepsis. The appreciation that the consequences of sepsis are a result not of the pathogen, but rather the immune response to the pathogen, dates back to observations made by William Osler in 1904 in his book, The Evolution of Modern Medicine. Accordingly, the idea that sepsis might be most effectively treated by immunomodulation is not new. With the identification of tumor necrosis factor (TNF) and interleukin-1b (IL-1b) as major inflammatory cytokines in models of sepsis in the last part of the twentieth century, trials were undertaken to block these cytokines to treat septic cytokine storm.

Pro-inflammatory Cytokines

  • NFkB

  • Interleukin-1 (IL1)

  • Interleukin-6 (IL6)

  • Interleukin-7 (IL7)

  • Interleukin-8 (IL8) 

  • Interleukin-12 (IL12)

  • Interleukin-15 (IL15)

  • Interleukin-17 (IL17)

  • Interleukin-18 (IL18)

  • Tumour Necrosis Factor (TNFa)

  • IgF1

  • MMP9

  • GlycA

  • S100B

  • TGFβ Signaling

  • Nagalase

  • HIF

Anti-inflammatory Cytokines


  • ​Nrf2

  • P53

  • GM-CSF (Granulocyte Macrophage Colony Stimulating Factor)

  • Interleukin-2 (IL2)

  • Interleukin-3 (IL3)  

  • Interleukin-4 (IL4)

  • Interleukin-5 (IL5)

  • Interleukin-10 (IL10)

  • Interleukin-13 (IL13)

  • Interleukin-21 (IL21)

  • Brain Derived Neural Growth Factors (BDNF, GDNF)

  • Vascular Growth Factors (VEGF)

  • IGF1

Adv Drug Deliv Rev. 2017 Feb 15. pii: S0169-409X(17)30028-5. doi: 10.1016/j.addr.2017.02.001. [Epub ahead of print]

Mimicking Oxygen delivery and waste removal functions of blood.

Zhang H1, Barralet JE2.

Author information


In addition to immunological and wound healing cell and platelet delivery, ion stasis and nutrient supply, blood delivers oxygen to cells and tissues and removes metabolic wastes. For decades researchers have been trying to develop approaches that mimic these two immediately vital functions of blood. Oxygen is crucial for the long-term survival of tissues and cells in vertebrates. Hypoxia (oxygen deficiency) and even at times anoxia (absence of oxygen) can occur during organ preservation, organ and cell transplantation, wound healing, in tumors and engineering of tissues. Different approaches have been developed to deliver oxygen to tissues and cells, including hyperbaric oxygen therapy (HBOT), normobaric hyperoxia therapy (NBOT), using biochemical reactions and electrolysis, employing liquids with high oxygen solubility, administering hemoglobin, myoglobin and red blood cells (RBCs), introducing oxygen-generating agents, using oxygen-carrying microparticles, persufflation, and peritoneal oxygenation. Metabolic waste accumulation is another issue in biological systems when blood flow is insufficient.

Metabolic wastes change the microenvironment of cells and tissues, influence the metabolic activities of cells, and ultimately cause cell death. This review examines advances in blood mimicking systems in the field of biomedical engineering in terms of oxygen delivery and metabolic waste removal.

OXYMED Australia

643 Chapel Street South Yarra 3141 Australia

T: +61 3 9826 9898  E: